Efficacy and Safety of Iodixanol in Computed Coronary Tomographic Angiography and Cardiac Catheterization.
Matthew J BudoffHong Seok LeeSion K RoyChandana ShekarPublished in: Journal of cardiovascular development and disease (2023)
Iodixanol is an iso-osmolar non-ionic dimeric hydrophilic contrast agent with a higher viscosity than the monomeric agents. It is the only Food and Drug Administration (FDA)-approved iso-osmolar agent in the United States, and it is the only contrast agent with an FDA-approved indication for use in cardiac computed tomographic angiography (CCTA), to assist in the diagnostic evaluation of patients with suspected coronary artery disease. In clinical studies, it has been noted to have fewer side effects and similar image quality when compared to low-osmolar contrast media. This can be attributed to the pharmacological properties of iodixanol. These contrast agents are used for coronary computed tomography angiography and cardiac catheterization. In this article, the use, tolerability, and efficacy of iodixanol are reviewed, specifically evaluating the use of CCTA and coronary angiography, including outcome studies, randomized trials, and comparisons to other contrast agents.
Keyphrases
- coronary artery disease
- drug administration
- magnetic resonance
- image quality
- computed tomography
- coronary artery
- contrast enhanced
- left ventricular
- optical coherence tomography
- magnetic resonance imaging
- percutaneous coronary intervention
- heart failure
- ultrasound guided
- open label
- randomized controlled trial
- clinical trial
- risk assessment
- aortic stenosis
- mass spectrometry
- study protocol
- human health
- diffusion weighted imaging
- climate change
- ejection fraction